Christian von Drehle’s global health work focuses predominately on informing policy decisions across communicable diseases (HIV/AIDS, tuberculosis, malaria), immunisation, non-communicable diseases, and maternal, newborn and child health. Some of his recent health projects included the large scale thematic review of the Global Fund’s approach to investments in Resilient and Sustainable Systems for Health; an analysis of potential externalities from Gavi’s market shaping activities; a Return on Investment study for the Global Financing Facility in support of Every Women Every Child; and an analysis of the factors affecting health financing for sexual, reproductive, maternal, newborn, child and adolescent health, funded by the Partnership for Maternal, Newborn and Child Health. Christian has also conducted work in the area of health economics for other clients including the World Health Organization (WHO), Unitaid and the Malaria Consortium.
In the energy sector, Christian has assisted a UK regulator in conducting an impact assessment of its price control proposals. His energy modelling work included a project for a South Asian regulator for which CEPA developed a comprehensive wholesale energy market model that was used to inform on their current energy market design.
Prior to joining CEPA, Christian worked as a consultant in the research and policy unit in the Global Polio Eradication Initiative at WHO.
Christian holds two Master’s degrees with distinction; a Master's in International Public Management from Sciences Po Paris and a MSc in International Political Economy from the London School of Economics. He also holds a first-class Bachelor’s degree in Land Economy from the University of Cambridge.
Recent News & insights
Our report on “Accelerating the Equitable Deployment and Access to Innovations” is published by the Global Fund
A technical evaluation by CEPA's Global Health team, to assess how the Global Fund is performing in terms of supporting innovations.
Modelling the impact of a patent pool for essential medicines in low- and middle-income countries
The Medicines Patent Pool (MPP) is a Geneva-based organisation that negotiates and manages licences for essential medicines, which it makes available to generic manufacturers for the benefit of low- and lower-income countries.
CEPA evaluates Unitaid’s investments in Hepatitis C
Unitaid has invested more than US$45 million since 2015 in support of improving access to care for hepatitis C. We are pleased to have provided them with a portfolio evaluation and end of grant evaluations.
Unitaid molecular diagnostics portfolio review
CEPA was appointed by Unitaid to conduct a portfolio-level joint end-of-grant evaluation of its investments in Point of Care (POC) molecular diagnostics for HIV.
Gavi supply and procurement strategy evaluation
CEPA was appointed by Gavi to conduct an evaluation of the 2016-20 Supply and Procurement Strategy (their market shaping strategy). This large-scale evaluation involved an assessment of the design, implementation and results of the strategy.
TERG / Global Fund HIV primary prevention review
The Global Fund Technical Evaluation Reference Group (TERG) commissioned CEPA to conduct a review of the Global Fund’s investments in HIV primary prevention.
Evaluation of Unitaid Next Generation Indoor Residual Spray (NgenIRS) project
Unitaid commissioned CEPA to conduct an end of project evaluation of the NgenIRS project which aimed to facilitate the creation of a sustainable market for third-generation Indoor Residual Spraying (3GIRS) products.
Unitaid long-acting HIV drugs modelling support
Unitaid commissioned CEPA to develop a model to quantify the potential uptake and impact of long-acting drugs for anti-retroviral treatment of HIV.
Gavi eligibility and transition and co-financing policy evaluation
Evaluation of Gavi’s Eligibility and Transition and Co-financing Policies.